Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] Arribas [14], Caraco[6],Fischer[7], Bernal[4], Khoo[8], Zou[3] 800 mg 800 mg 800 mg 800 mg 800 mg 800 mg 800 mg 800 mg
Outcome Outcome Outcome No. of participants (studies) No. of participants (studies) Effect estimate (95% CI) Risk of bias Risk of bias Inconsistency Inconsistency Inconsistency Indirectness Indirectness Imprecision Imprecision Imprecision
A.Virology Profile 1.SARS-COV-2 RNA ERROR RATE A.Virology Profile 1.SARS-COV-2 RNA ERROR RATE A.Virology Profile 1.SARS-COV-2 RNA ERROR RATE
145
145
MD 1.71 [-0.11, 3.53]
Low
Low
Moderate
Moderate
Moderate
Not Serious
Not Serious
Serious
Serious
Serious
2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 775 775 OR 1.90 [0.80, 4.53] Low Low Moderate Moderate Moderate Not Serious Not Serious Serious Serious Serious
3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 4534 4534 MD -0.17 [-0.29, -0.06] Low Low Mild Mild Mild Not Serious Not Serious Not Serious Not Serious Not Serious
B. Mortality B. Mortality B. Mortality 1823 1823 RR 0.48 [0.12, 1.98] Low Low Mild Mild Mild Not Serious Not Serious Serious Serious Serious
Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] Arribas[14], Caraco[6],Fischer[7] 400 mg 400 mg 400 mg 400 mg 400 mg 400 mg 400 mg
Outcome Outcome No. of participants (studies) No. of participants (studies) Effect estimate (95% CI) Effect estimate (95% CI) Effect estimate (95% CI) Risk of bias Risk of bias Inconsistency Inconsistency Inconsistency Indirectness Indirectness Imprecision Publication bias
A.Virological Profile 1.SARS-COV-2 RNA ERROR RATE A.Virological Profile 1.SARS-COV-2 RNA ERROR RATE
161
161
MD 2.57 [0.50, 4.65]
MD 2.57 [0.50, 4.65]
MD 2.57 [0.50, 4.65]
Low
Low
Low
Low
Low
Not Serious
Not Serious
Serious
N/A
2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 2. Time for clearance SARS-COV-2 or undetectable SARS-COV-2 in the nasopharyngeal sample 657 657 OD 0.81 [0.45, 1.45] OD 0.81 [0.45, 1.45] OD 0.81 [0.45, 1.45] Low Low Mild Mild Mild Not Serious Not Serious Serious N/A
3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 3. Mean change in SARS-COV-2 from baseline in nasopharyngeal sample 466 466 MD -0.28 [-0.49, -0.07] MD -0.28 [-0.49, -0.07] MD -0.28 [-0.49, -0.07] Low Low Low Low Low Not Serious Not Serious Not Serious N/A
B. Mortality B. Mortality 423 423 RR 0.17 [0.07, 0.43] RR 0.17 [0.07, 0.43] RR 0.17 [0.07, 0.43] Low Low Low Low Low Not Serious Not Serious Serious N/A